What is the effect of Estradiol vaginal for APOE4 carriers?
Phoenix has measured Estradiol vaginal against 1 exact outcome for APOE4 carriers. Member #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days.
Browse by intervention
One intervention, every measured benefit and result that did not improve. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.
How to read this
Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.
Read the full methods and limitsPhoenix has measured Estradiol vaginal against 1 exact outcome for APOE4 carriers. Member #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days.
| Outcome | Direction | What we observed |
|---|---|---|
| HDL cholesterol | Positive individual result | Member #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days. |
Vaginal estrogen lowers repeat urinary tract infections after menopause and probably eases vaginal dryness, with very little reaching the bloodstream. In breast cancer survivors, studies so far have not found worse survival, but that decision belongs with your oncologist. A brain benefit is not proven; the idea is indirect, via fewer UTIs, which can cause confusion in older adults.
APOE4-specific evidence: none
Trials show vaginal estrogen cuts repeat urinary infections by more than half and probably eases vaginal symptoms; any brain benefit is untested.
Chen 2021, Int Urogynecol J
Meta-analysis: vaginal estrogen cut recurrent UTIs (RR 0.42, 5 trials); oral estrogen did not.
Read on PubMed (opens in a new tab)Perrotta 2008, Cochrane
Vaginal, not oral, estrogen reduced recurrent UTIs in two small placebo trials.
Read on PubMed (opens in a new tab)Raz 1993, N Engl J Med
RCT: vaginal estriol sharply reduced recurrent UTIs versus placebo.
Read on PubMed (opens in a new tab)Lethaby 2016, CochraneGrade B
Low-quality evidence that vaginal estrogen improves vaginal atrophy symptoms; preparations similar to each other.
Read on PubMed (opens in a new tab)Mitchel 2026, JCO Oncol Pract
SEER cohort of breast cancer survivors over 65: vaginal estrogen not linked to worse overall or cancer-specific survival.
Read on PubMed (opens in a new tab)5 passages for, 1 with a caution
Now showing: Dr. Ashanthi Gajaweera · 38:07
Open on YouTube (opens in a new tab)
Vaginal estrogen lowers UTI risk, and UTIs can harm thinking.
“vaginal estrogen is really important in all women regardless of their dementia risk in order to reduce their UTI risk because UTI compromises cognition.”
Dr. Ashanthi Gajaweera, Board-certified neurologist, Menopause Society certified practitioner (Healthspan Neurology)

Postmenopausal women should be on vaginal estrogen; almost no contraindications, she says.
“post-menopausal women they should be on vaginal estrogen almost no contraindications to that.”
Dr. Ashanthi Gajaweera, Board-certified neurologist, Menopause Society certified practitioner (Healthspan Neurology)

Vaginal estrogen helps prevent recurring UTIs.
“it is a very effective way to prevent chronic UTI.”
Steve Goldring, Menopause hormone educator (Simple Hormones), 30+ years in compounding pharmacy

Every woman after menopause should be offered vaginal estradiol.
“every postmenopausal woman should be at least offered vaginal estradiol for a couple of different reasons.”
Steve Goldring, Menopause hormone educator (Simple Hormones), 30+ years in compounding pharmacy

Vaginal estrogen barely reaches the bloodstream.
“So, the amount of estradiol that you get is negligible.”
Steve Goldring, Menopause hormone educator (Simple Hormones), 30+ years in compounding pharmacy

Breast cancer survivors may still use vaginal estrogen with their team.
“who have gone through breast cancer and who are not allowed by their provider to take estrogen in an oral or a transdermal form can take a vaginal estrogen cream.”
Steve Goldring, Menopause hormone educator (Simple Hormones), 30+ years in compounding pharmacy
Last reviewed
Phoenix has measured Estradiol vaginal against 1 exact outcome for APOE4 carriers. Member #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days.
Member #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.
Search by health goal or intervention to see what changed for real members, including results that moved the wrong way.
Want to see how this affects you? Phoenix tracks it beside your labs and how you feel.
Apply to join PhoenixEstradiol vaginal · 1 outcome shown.
HDL cholesterol: Increase 26 mg/dL
Cases: 1
Estradiol vaginal
✓Positive individual resultMember #EFF528's HDL cholesterol moved from 53 to 79 mg/dL in 338 days.
HDL cholesterol
Before53After79mg/dL+49.1%
338 days between measurements
Full stack credited: Estradiol vaginal (lead), Ezetimibe (undated).
What else changed: no nearby starts were recorded.
Next study: repeat HDL cholesterol after a dated Estradiol vaginal window.
The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.
Turn evidence into your next test
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.